Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio.

BEACON and Open-Label Extension Study Design and Data Summary: ...

NMRA-861 has demonstrated a potentially best-in-class pharmacological profile and robust activity in preclinical efficacy models. NMRA-861 was safe and well-tolerated in pre-clinical toxicology ...

The clinical trial support services market is experiencing significant growth, driven by the increasing incidence of chronic illnesses such as cancer, diabetes, and cardiovascular diseases. This rise ...

Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on ...

In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plusdarolutamide in men with metastatic castration resistant prostate cancer ("mCRPC"),the six-month radiographic progres ...

Participants in the trial will undergo all three screening methods like mammography, ultrasound and the AI-based scan to ...

Apogee Therapeutics said its antibody treatment alleviated signs and symptoms of atopic dermatitis far more than a placebo — ...

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

The Karnataka government has asked the Central Drugs Standard Control Organisation to investigate alleged clinical trial ...

The project aims to understand the impact of existing therapies as forms of intervention on hospital outcomes, as well as one-year clinical outcomes, and to use appropriate measures to prevent them.

Northwestern University hasn’t received any funding from the NIH since the end of March. Not only could patients potentially stop receiving treatments that trials provided, the research itself could ...